The following guideline can be ordered through the address listed in the "Source/Publisher"-category. In cases in which you can order through the Internet we have established a hyperlink.

Bridging for Drug-Device and Biologic-Device Combination Products

Origin/Publisher:

FDA

Document Type:
Daft Guidance
Content:
This guidance provides recommendations to industry and FDA staff on how to approach bridging in new drug applications (NDAs) or biologics license applications (BLAs) for drug device and biologic-device single entity or copackaged combination products.

Go back

GMP Conferences by Topics